Ad hoc:MediGene AG:Ad hoc:MediGene sells full European.

   ·     Astellas to make one-off payments totaling EUR 25 million
   ·     Medigene to remain entitled to royalties
   ·     No further costs to MediGene
   ·     Sale price reflects the full NPV of all future Eligard(® )revenues
while allowing MediGene to benefit from continued Eligard(®) growth
   ·     Analyst and press conference call and webcast tomorrow, July 20, at 11
a.m. (CEST)

Martinsried/Munich, July 19, 2010.  MediGene AG (Frankfurt, Prime Standard, MDG,
TecDAX) announces the sale of full European marketing and distribution rights to
Eligard(®) (leuprolide acetate, for the treatment of hormone-dependent prostate
cancer) to Astellas Pharma Europe Ltd. (London, "Astellas"), previously
MediGene's European marketing partner for Eligard(®). MediGene acquired these
rights from TOLMAR Therapeutics Inc. (formerly Atrix Laboratories Inc.) in
2001. In return for the Eligard(®) license, MediGene will receive EUR 25 million
in cash from Astellas as well as royalties on future product sales. For
MediGene, all future costs, obligations and risks associated with the supply of
Eligard(® )to Astellas, as well all future procurement costs and license
payments to TOLMAR, will cease within the next months.

This agreement will strengthen MediGene's financial situation and provide the
opportunity for MediGene to profit from future growth of Eligard(®) sales. This
would not be possible under the former deal structure since MediGene's net
margin decreased once net sales by Astellas exceeded a certain threshold,
capping royalty receipts. The new agreement reflects the full NPV of all future
Eligard(®) revenues according to the previous deal structure.

MediGene will now receive a low single-digit royalty on net sales of Eligard(®)
generated by Astellas in Europe.  In 2009, MediGene's net participation in
Eligard(®) sales by Astellas totalled about 6%. In future, MediGene will receive
about one third of this margin on Eligard(®) in-market sales. According to the
contract, Astellas will pay EUR 25 million in three tranches as the steps of
transfer of the rights are concluded over the next six to twelve months (EUR 5
million upon signature, EUR 15 million anticipated within six to eight months,
EUR 5 million anticipated within six to twelve months).

Analyst and press conference call and webcast: An analyst and press conference
call in English will take place tomorrow, July 20, at 11 a.m. (CEST), and will
be webcast live. The webcast and synchronized presentation slides can be
accessed at www.medigene.com. A recording of the live presentation will also be
available thereafter.

This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.

- ends -


Contact MediGene AG

Email: investor@medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946



[HUG#1432648]



--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: 502090;ISIN: DE0005020903;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;





This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: MediGene AG via Thomson Reuters ONE